N-(tert-Butyl)-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

Catalog No. :
ACYONB249
CAS No. :
2377609-40-8
Molecular Formula :
C18H28BNO3
Molecular Weight :
317.24

IUPAC Name:N-(tert-butyl)-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

N-(tert-Butyl)-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$137.00Login to see priceInquiryInquiry
1g95%$312.00Login to see priceInquiryInquiry
5g95%$895.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(tert-Butyl)-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide
IUPAC NameN-(tert-butyl)-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide
Molecular FormulaC18H28BNO3
Molecular Weight317.24
SMILESO=C(CC1=CC=CC(B2OC(C)(C(C)(O2)C)C)=C1)NC(C)(C)C
InChI KeyHTTVHMLFGVBRSK-UHFFFAOYSA-N
Synonym3-[(t-Butylcarbamoyl)methyl]phenylboronic acid, pinacol ester;N-(tert-butyl)-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide;Benzeneacetamide, N-(1,1-dimethylethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.2377609-40-8

Synthetic Route by SureRoute

1. ACYONB249 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  4. Then
  5. ACYONB249 route product structure diagram
    ACYONB2492377609-40-8
Inquiry

2. ACYONB249 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACPLCQ651 route compound structure diagram
    ACPLCQ65160469-70-7
  2. Plus
  3. ACBPFG782 route compound structure diagram
    ACBPFG782797755-05-6 In Stock
  4. Then
  5. ACYONB249 route product structure diagram
    ACYONB2492377609-40-8
Inquiry

Comments (0)